Clinical Trials Market 
                     Clinical Trials Market
Global Forecast to 2026
Clinical Trial Market is 
expected to reach 
$ 52.0 Billion by 2026
Growing at a 
CAGR of  6.1% (2021 – 2026)
The clinical trials market is projected to reach USD 52.0 billion by 
2026 from USD 38.7 billion in 2021, at a CAGR of 6.1% during the 
forecast period.
Laboratory services segment accounted for the largest share of the clinical trials market
Based on service type, the clinical trials market is segmented into protocol designing, site identification, patient 
recruitment, laboratory services, bioanalytical testing, analytical testing, clinical trial supply & logistic services, 
decentralized clinical services, clinical trial data management services, medical device testing services, and other 
services. Laboratory services is the leading segment of clinical trial services market, this can be attributed to the 
increasing preference of clinical research professionals to outsource such services. Among all the aspects of 
conducting clinical trials (such as protocol designing, site identification, and patient recruitment, among others), 
laboratory services have witnessed comparatively high outsourcing rates in the past few years, thus contributing to 
the growth of this segment.
Oncology segment accounted for the largest share of the clinical trials market
Based on the therapy area, the clinical trials market is segmented into oncology, infectious 
diseases, cardiology, neurology, womens health, genetic diseases, immunology, and other 
therapeutic areas. The large share of oncology segment is primarily attributed to the increasing 
number of drug discovery activities for oncology and the rising prevalence of cancer worldwide.
        
 Small molecules segment accounted for the largest share of clinical trials market
        The clinical trials market is segmented into small molecules, vaccines, cell & gene 
therapy, and others based on application. Small molecules is the key driver of the clinical 
trials application market, regardless of the synthetic method and materials used, small 
molecules are able to retain their chemical identity as opposed to sensitive biologics 
candidates, which has contributed to the robust demand for small molecule drug candidates. 
The majority of the patented drugs marketed in the past five years have been small 
molecules and generics of these patented drugs.